
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is poised for success in the coming years, with a strong financial outlook and multiple avenues for growth. The company's partnerships with Smith & Nephew and its continued focus on innovation suggest potential upside to its initial mid-teens growth outlook. They have a solid revenue beat in 4Q and increased both gross margins and adjusted EBITDA. Analysts expect continued growth and profitability as SIBN's technology expands into new markets, making it a solid choice for investors.
Bears say
SI-BONE is a medical device company that develops and commercializes minimally invasive surgical implants and instruments for sacroiliac joint dysfunction, adult spinal deformity and degeneration, and pelvic trauma. Despite management's efforts to drive adoption and expand partnerships, the company's revenue growth has been weak internationally and may face challenges in the US due to lower-than-expected market penetration and sluggish adoption by surgeons. Additionally, the company's bear case scenario, assuming low-teens revenue growth, corresponds to a significant decline in stock value to $15 per share, indicating overall weakness in financial performance.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares